Danish medical software company Brain+ A/S (Nasdaq First North:BRAINP) on Thursday reported strong results from a post market clinical follow-up study of its Ayla dementia care platform in two UK care homes.

Over seven weeks, residents with mild to moderate dementia who received twice-weekly Cognitive Stimulation Therapy (CST) sessions supported by Ayla showed a 47.8% improvement in overall cognitive outcomes.

Key gains included a 56.5% increase in recognition and memory, a 42.3% improvement in communication and understanding, and a 66.3% increase in planning abilities. Task-switching skills rose by 48.3%, while mood and quality-of-life scores also improved across energy, memory, and self-perception measures.

The study was conducted by Southcare Homes Group, Brain+'s first paid partner for Ayla. Following the pilot's success, Southcare has contracted to deploy Ayla across its full care home network.

CST is endorsed by NICE and the World Health Organisation as a leading non-drug therapy for dementia, though delivery at scale is limited by training and preparation demands. Brain+ positions Ayla as a digital solution that reduces preparation time, integrates into daily routines, and enables consistent, personalised therapy in care homes.

The company said that the findings validate Ayla's relevance in dementia care and are expected to accelerate sales pipeline conversion.